What do Cochrane systematic reviews say about the use of cannabinoids in clinical practice?

Detalhes bibliográficos
Autor(a) principal: Latorraca,Carolina de Oliveira Cruz
Data de Publicação: 2018
Outros Autores: Pacheco,Rafael Leite, Martimbianco,Ana Luiza Cabrera, Pachito,Daniela Vianna, Riera,Rachel
Tipo de documento: Artigo
Idioma: eng
Título da fonte: São Paulo medical journal (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802018000500472
Resumo: ABSTRACT BACKGROUND: The therapeutic effects of cannabinoid compounds have been the center of many investigations. This study provides a synthesis on all Cochrane systematic reviews (SRs) that assessed the use of cannabinoids as a therapeutic approach. DESIGN AND SETTING: Review of SRs, conducted in the Discipline of Evidence-Based Medicine, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP). METHODS: A broad search was conducted in the Cochrane Database of Systematic Reviews to retrieve any Cochrane SRs that assessed the efficacy and safety of cannabinoids as a therapeutic approach. The results and key characteristics of all reviews included were summarized and discussed. RESULTS: Eight SRs were included. They assessed the use of cannabinoids for the following types of conditions: neurological (two SRs), psychiatric (two SRs), rheumatological (one SR), infectious (one SR) and oncological (two SRs). There was moderate-quality evidence showing that the use of cannabinoids reduced nausea and vomiting among adults, compared with placebo. Additionally, there was moderate-quality evidence showing that there was no difference between cannabinoids and prochlorperazine regarding the number of participants who reported vomiting, in this same population. CONCLUSIONS: This review identified eight Cochrane systematic reviews that provided evidence of unknown to moderate quality regarding the use of cannabinoids as a therapeutic intervention. Further studies are still imperative for solid conclusions to be reached regarding practical recommendations.
id APM-1_fe37cbdc4e4c8992c124532ad5d58c37
oai_identifier_str oai:scielo:S1516-31802018000500472
network_acronym_str APM-1
network_name_str São Paulo medical journal (Online)
repository_id_str
spelling What do Cochrane systematic reviews say about the use of cannabinoids in clinical practice?Review [publication type]Evidence-based medicineEvidence-based practiceCannabisCannabinoidsABSTRACT BACKGROUND: The therapeutic effects of cannabinoid compounds have been the center of many investigations. This study provides a synthesis on all Cochrane systematic reviews (SRs) that assessed the use of cannabinoids as a therapeutic approach. DESIGN AND SETTING: Review of SRs, conducted in the Discipline of Evidence-Based Medicine, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP). METHODS: A broad search was conducted in the Cochrane Database of Systematic Reviews to retrieve any Cochrane SRs that assessed the efficacy and safety of cannabinoids as a therapeutic approach. The results and key characteristics of all reviews included were summarized and discussed. RESULTS: Eight SRs were included. They assessed the use of cannabinoids for the following types of conditions: neurological (two SRs), psychiatric (two SRs), rheumatological (one SR), infectious (one SR) and oncological (two SRs). There was moderate-quality evidence showing that the use of cannabinoids reduced nausea and vomiting among adults, compared with placebo. Additionally, there was moderate-quality evidence showing that there was no difference between cannabinoids and prochlorperazine regarding the number of participants who reported vomiting, in this same population. CONCLUSIONS: This review identified eight Cochrane systematic reviews that provided evidence of unknown to moderate quality regarding the use of cannabinoids as a therapeutic intervention. Further studies are still imperative for solid conclusions to be reached regarding practical recommendations.Associação Paulista de Medicina - APM2018-10-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802018000500472Sao Paulo Medical Journal v.136 n.5 2018reponame:São Paulo medical journal (Online)instname:Associação Paulista de Medicinainstacron:APM10.1590/1516-3180.2018.0313210818info:eu-repo/semantics/openAccessLatorraca,Carolina de Oliveira CruzPacheco,Rafael LeiteMartimbianco,Ana Luiza CabreraPachito,Daniela ViannaRiera,Racheleng2018-12-17T00:00:00Zoai:scielo:S1516-31802018000500472Revistahttp://www.scielo.br/spmjhttps://old.scielo.br/oai/scielo-oai.phprevistas@apm.org.br1806-94601516-3180opendoar:2018-12-17T00:00São Paulo medical journal (Online) - Associação Paulista de Medicinafalse
dc.title.none.fl_str_mv What do Cochrane systematic reviews say about the use of cannabinoids in clinical practice?
title What do Cochrane systematic reviews say about the use of cannabinoids in clinical practice?
spellingShingle What do Cochrane systematic reviews say about the use of cannabinoids in clinical practice?
Latorraca,Carolina de Oliveira Cruz
Review [publication type]
Evidence-based medicine
Evidence-based practice
Cannabis
Cannabinoids
title_short What do Cochrane systematic reviews say about the use of cannabinoids in clinical practice?
title_full What do Cochrane systematic reviews say about the use of cannabinoids in clinical practice?
title_fullStr What do Cochrane systematic reviews say about the use of cannabinoids in clinical practice?
title_full_unstemmed What do Cochrane systematic reviews say about the use of cannabinoids in clinical practice?
title_sort What do Cochrane systematic reviews say about the use of cannabinoids in clinical practice?
author Latorraca,Carolina de Oliveira Cruz
author_facet Latorraca,Carolina de Oliveira Cruz
Pacheco,Rafael Leite
Martimbianco,Ana Luiza Cabrera
Pachito,Daniela Vianna
Riera,Rachel
author_role author
author2 Pacheco,Rafael Leite
Martimbianco,Ana Luiza Cabrera
Pachito,Daniela Vianna
Riera,Rachel
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Latorraca,Carolina de Oliveira Cruz
Pacheco,Rafael Leite
Martimbianco,Ana Luiza Cabrera
Pachito,Daniela Vianna
Riera,Rachel
dc.subject.por.fl_str_mv Review [publication type]
Evidence-based medicine
Evidence-based practice
Cannabis
Cannabinoids
topic Review [publication type]
Evidence-based medicine
Evidence-based practice
Cannabis
Cannabinoids
description ABSTRACT BACKGROUND: The therapeutic effects of cannabinoid compounds have been the center of many investigations. This study provides a synthesis on all Cochrane systematic reviews (SRs) that assessed the use of cannabinoids as a therapeutic approach. DESIGN AND SETTING: Review of SRs, conducted in the Discipline of Evidence-Based Medicine, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP). METHODS: A broad search was conducted in the Cochrane Database of Systematic Reviews to retrieve any Cochrane SRs that assessed the efficacy and safety of cannabinoids as a therapeutic approach. The results and key characteristics of all reviews included were summarized and discussed. RESULTS: Eight SRs were included. They assessed the use of cannabinoids for the following types of conditions: neurological (two SRs), psychiatric (two SRs), rheumatological (one SR), infectious (one SR) and oncological (two SRs). There was moderate-quality evidence showing that the use of cannabinoids reduced nausea and vomiting among adults, compared with placebo. Additionally, there was moderate-quality evidence showing that there was no difference between cannabinoids and prochlorperazine regarding the number of participants who reported vomiting, in this same population. CONCLUSIONS: This review identified eight Cochrane systematic reviews that provided evidence of unknown to moderate quality regarding the use of cannabinoids as a therapeutic intervention. Further studies are still imperative for solid conclusions to be reached regarding practical recommendations.
publishDate 2018
dc.date.none.fl_str_mv 2018-10-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802018000500472
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802018000500472
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/1516-3180.2018.0313210818
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Paulista de Medicina - APM
publisher.none.fl_str_mv Associação Paulista de Medicina - APM
dc.source.none.fl_str_mv Sao Paulo Medical Journal v.136 n.5 2018
reponame:São Paulo medical journal (Online)
instname:Associação Paulista de Medicina
instacron:APM
instname_str Associação Paulista de Medicina
instacron_str APM
institution APM
reponame_str São Paulo medical journal (Online)
collection São Paulo medical journal (Online)
repository.name.fl_str_mv São Paulo medical journal (Online) - Associação Paulista de Medicina
repository.mail.fl_str_mv revistas@apm.org.br
_version_ 1754209266316607488